PE20061294A1 - Formulacion de tableta estable que contiene polimorfo b de (6r)-l-eritro-tetra hidrobiopterina - Google Patents

Formulacion de tableta estable que contiene polimorfo b de (6r)-l-eritro-tetra hidrobiopterina

Info

Publication number
PE20061294A1
PE20061294A1 PE2005001350A PE2005001350A PE20061294A1 PE 20061294 A1 PE20061294 A1 PE 20061294A1 PE 2005001350 A PE2005001350 A PE 2005001350A PE 2005001350 A PE2005001350 A PE 2005001350A PE 20061294 A1 PE20061294 A1 PE 20061294A1
Authority
PE
Peru
Prior art keywords
formulation
weight
erythro
amount
polymorph
Prior art date
Application number
PE2005001350A
Other languages
English (en)
Inventor
Steven Jungles
Mark Henderson
Robert Baffi
Victoria Sluzky
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35849290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061294(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PE20061294A1 publication Critical patent/PE20061294A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN POLIMORFO CRISTALINO DE (6R)-L-ERITRO-TETRAHIDROBIOPTERINA (POLIMORFO B) QUE PRESENTA UN PATRON DE DIFRACCION EN POLVO DE RAYOS X CON LOS SIGUIENTES PICOS EXPRESADOS EN (Å): 8.7 (vs), 5.63 (m), 4.76 (m), 4.40 (m), 4.00(s), 3.23 (s), 3.11 (vs), ENTRE OTROS, EN UNA CANTIDAD COMPRENDIDA ENTRE 30% A 40% EN PESO DE LA FORMULACION; B) UN AGLUTINANTE TAL COMO FOSFATO CALCICO DIBASICO ANHIDRO EN UNA CANTIDAD COMPRENDIDA ENTRE 1% A 5% POR PESO DE LA FORMULACION; C) UN AGENTE DE DESINTEGRACION TAL COMO CROSPOVIDONA EN UNA CANTIDAD COMPRENDIDA ENTRE 3% A 10% POR PESO DE LA FORMULACION; D) UN ANTIOXIDANTE ACIDO TAL COMO ACIDO ASCORBICO EN UNA CANTIDAD COMPRENDIDA ENTRE 1% A 3% POR PESO DE LA FORMULACION; E) UN LUBRICANTE TAL COMO FUMARATO DE ESTEARILO EN UNA CANTIDAD COMPRENDIDA ENTRE 0.1% A 2% POR PESO DE LA FORMULACION; Y F) ADEMAS COMPRENDE VITAMINA B2, B12, UN FOLATO Y ARGININA. LA COMPOSICION SE PRESENTA EN FORMA DE TABLETA Y RETIENE AL MENOS 95% DE LA CANTIDAD INICIAL DE (6R)-L-ERITRO-TETRAHIDROBIOPTERINA DESPUES DE SEIS A NUEVE MESES A TEMPERATURA AMBIENTE Y 60% DE HUMEDAD. DICHA FORMULACION ES UTIL EN EL TRATAMIENTO DE TRANSTORNOS METABOLICOS TALES COMO DIABETES, HIPERINSULINEMIA
PE2005001350A 2004-11-17 2005-11-17 Formulacion de tableta estable que contiene polimorfo b de (6r)-l-eritro-tetra hidrobiopterina PE20061294A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62918904P 2004-11-17 2004-11-17

Publications (1)

Publication Number Publication Date
PE20061294A1 true PE20061294A1 (es) 2006-12-18

Family

ID=35849290

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001350A PE20061294A1 (es) 2004-11-17 2005-11-17 Formulacion de tableta estable que contiene polimorfo b de (6r)-l-eritro-tetra hidrobiopterina

Country Status (15)

Country Link
US (2) US8003126B2 (es)
EP (2) EP1845952A2 (es)
JP (2) JP2008520574A (es)
KR (1) KR20070084270A (es)
CN (1) CN101132776A (es)
AR (1) AR052238A1 (es)
AU (1) AU2005306686B2 (es)
BR (1) BRPI0517088A (es)
CA (1) CA2581814C (es)
IL (1) IL182161A (es)
MX (1) MX2007005039A (es)
MY (1) MY142120A (es)
PE (1) PE20061294A1 (es)
TW (1) TW200624120A (es)
WO (1) WO2006055511A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
BRPI0416566A (pt) 2003-11-17 2007-01-23 Biomarin Pharm Inc tratamento de fenilcetonúrias com bh4
DK1757293T3 (da) * 2004-05-11 2012-10-22 Daiichi Sankyo Co Ltd Bh4-responsiv hyperphenylalaninæmi-medikamenter
MX2007005039A (es) 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
US20100009997A1 (en) * 2007-01-12 2010-01-14 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
EP2114944A2 (en) * 2007-01-12 2009-11-11 BioMarin Pharmaceutical Inc. Tetrahydrobiopterin prodrugs
DK2139485T3 (da) 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
ECSP077628A (es) * 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
ES2524026T3 (es) * 2008-01-03 2014-12-03 Biomarin Pharmaceutical Inc. Análogo de pterina para tratar una afección que responde a BH4
WO2010017570A2 (de) * 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
WO2012127431A1 (en) * 2011-03-24 2012-09-27 Rubicon Research Private Limited Stabilized compositions of tetrahydrobiopterin
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
CN102775408B (zh) * 2012-01-20 2015-09-02 连云港金康医药科技有限公司 稳定的5-甲基四氢叶酸晶型及其制备方法
CN104530051B (zh) * 2012-01-20 2016-08-24 连云港金康和信药业有限公司 稳定的(6r,s)-5-甲基四氢叶酸晶型及其制备方法
RS54973B1 (sr) 2014-03-31 2016-11-30 Vasopharm Gmbh Čvrste farmaceutske kompozicije koje uključuju derivate biopterina i upotreba takvih kompozicija
WO2017106130A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Process for preparing pharmaceutical compositions
WO2017106073A1 (en) * 2015-12-18 2017-06-22 Colgate-Palmolive Company Fast dissolving peroxymonosulfate composition
CN109715650B (zh) 2016-07-26 2024-03-08 生物马林药物股份有限公司 新颖腺相关病毒衣壳蛋白
EP3490536A1 (en) 2016-07-29 2019-06-05 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
US20180110781A1 (en) * 2016-10-24 2018-04-26 Research Foundation For Mental Hygiene, Inc. System and method for diagnosis and treatment of neuropsychiatric disorders
US10758462B2 (en) * 2016-11-16 2020-09-01 Colgate-Palmolive Company Oral care composition
CA3043499A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymorphic form of sepiapterin
IL266955B2 (en) * 2016-11-29 2023-09-01 Ptc Therapeutics Mp Inc Polymorphs of spiafatrin and its salts
JP2020532535A (ja) * 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー,インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
BR112020022722A8 (pt) 2018-05-09 2022-01-18 Biomarin Pharm Inc Genoma e seu uso, vetor, partícula, molécula de ácido nucleico isolada, ácido nucleico, composição, tratamento, método
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US11617752B2 (en) 2018-05-30 2023-04-04 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
TR201914406A2 (tr) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Sapropteri̇n di̇hi̇droklorür ve en az bi̇r farmasöti̇k eksi̇pi̇yan i̇çeren kati oral farmasöti̇k formülasyonlar
TR201914416A1 (tr) 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Sapropteri̇n di̇hi̇droklorürün efervesan formülasyonlari
TR201914420A2 (tr) * 2019-09-23 2021-04-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Sapropteri̇n di̇hi̇droklorür ve en az bi̇r anti̇oksi̇dan i̇çeren farmasöti̇k formülasyonlar
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2603643A (en) 1947-03-13 1952-07-15 Hoffmann La Roche 2-amino-4-hydroxy-6-polyhydroxyalkyl pteridine and methods of oxidizing same
US2601215A (en) 1948-03-17 1952-06-17 American Cyanamid Co Process of preparing dihydropterins
US2541717A (en) 1948-10-18 1951-02-13 Upjohn Co Pterine imines
US2568685A (en) 1950-07-22 1951-09-18 Upjohn Co 2-amino-4-hydroxy-6-omega-carboxytrihydroxy-propylpteridines
US2955110A (en) 1955-01-13 1960-10-04 American Cyanamid Co Substituted pteridines and method of preparing the same
US3505329A (en) 1968-02-06 1970-04-07 Smithkline Corp Process for the synthesis of biopterin
GB2056459B (en) 1979-07-04 1983-03-09 Daiichi Radioisotope Lab Pterin derivatives and an assay method for determining pterins
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
JPS5883691A (ja) 1981-11-13 1983-05-19 Kanegafuchi Chem Ind Co Ltd 1′,2′−ジアシル−(6r,s)−5,6,7,8−テトラヒドロ−l−ビオプテリンおよびその製法
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
JPS5921685A (ja) 1982-07-28 1984-02-03 Suntory Ltd L―エリスロ―バイオプテリンの製造法
AU572792B2 (en) 1982-09-20 1988-05-19 Wellcome Foundation Limited, The 2-amino, 4-oxo-pteridine derivatives
ZA836957B (en) 1982-09-20 1985-04-24 Wellcome Found Neurologically active chemical compounds
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
US5196533A (en) 1983-04-11 1993-03-23 South Alabama Medical Science Foundation, Usa Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en) 1983-09-19 1986-05-06 Burroughs Wellcome Co. Biopterin analogs
JPS60178887A (ja) 1984-02-23 1985-09-12 Kanegafuchi Chem Ind Co Ltd 5,6,7,8−テトラヒドロ−l−ビオプテリンの製造法
JPS60199889A (ja) 1984-03-24 1985-10-09 Kanegafuchi Chem Ind Co Ltd 5,6,7,8−テトラヒドロ−l−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en) 1984-05-31 1985-10-29 The Board Of Regents, The University Of Texas System Lipoidal biopterin compounds
DE3437944A1 (de) 1984-10-17 1986-07-31 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
JPS61172877A (ja) * 1985-01-28 1986-08-04 Shiratori Seiyaku Kk (6r)−テトラヒドロ−l−バイオプテリンの製造方法
CA1262347A (en) 1985-01-28 1989-10-17 Suntory Limited Preparation process of (6r)-tetrahydro-l-biopterin
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
ES2037672T3 (es) 1987-02-13 1993-07-01 Pharm-Allergan Gmbh Utilizacion de pteridinas y/o purinas o de un inhibidor de xantinoxidasa para la fabricacion de un medicamento para el tratamiento de enfermedades degenerativas de la retina condicionadas geneticamente.
JP2588191B2 (ja) * 1987-04-24 1997-03-05 サントリー株式会社 悪性腫瘍および重症ウイルス感染症に伴う神経症状を改善するための治療剤
EP0318926B1 (en) 1987-11-30 1995-05-03 Kabushiki Kaisha Vitamin Kenkyusyo Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives
EP0349204A3 (en) 1988-06-28 1991-08-07 Bend Research, Inc. Use and regeneration of reagents using coupled reactions and permselective barriers
JP2843592B2 (ja) 1989-02-28 1999-01-06 日清製粉株式会社 L−リボース誘導体
US5554647A (en) 1989-10-12 1996-09-10 Perricone; Nicholas V. Method and compositions for treatment and/or prevention of skin damage and aging
WO1991012814A1 (en) 1990-02-28 1991-09-05 E.I. Du Pont De Nemours And Company Activation of monocyte/macrophages
JP3137333B2 (ja) 1990-07-21 2001-02-19 サントリー株式会社 テトラヒドロビオプテリンの製法およびそれに用いる酵素
DE4037447C2 (de) 1990-11-24 1994-06-01 Milupa Ag Phenylalaninfreies Diätetikum für juvenile und adulte Personen mit Phenylketonurie sowie ein Verfahren zu seiner Herstellung
JPH04210624A (ja) 1990-12-11 1992-07-31 Shigenobu Sakata 薬用効果を有する入浴剤及び化粧水
WO1993010155A1 (en) 1991-11-16 1993-05-27 Suntory Limited 6(r)-l-erythro-5,6,7,8-tetrahydrobiopterin receptor
US5877176A (en) 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
JP2534423B2 (ja) 1991-12-26 1996-09-18 コーネル・リサーチ・ファンデーション・インコーポレイテッド 酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
DE4215275A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Mittel und Verfahren zur Behandlung von Körperflüssigkeiten bei der Bestimmung von Neopterin
US6251953B1 (en) 1992-10-30 2001-06-26 Andrew Brookner Beta-carotene therapy of individuals having abnormal immunological and serological indices, and individuals having infections and diseases causing changes therein
US5658565A (en) 1994-06-24 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase gene for treatment of disease
US5830461A (en) 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
US20020061862A1 (en) 1992-11-25 2002-05-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inducible nitric oxide synthase for treatment of disease
JPH08503852A (ja) 1992-11-25 1996-04-30 ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブハイヤー エデュケーション ヒト誘導性一酸化窒素シンターゼのcDNAクローンおよびその作製方法
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
DE4308739C1 (de) 1993-03-19 1994-06-23 Henning Berlin Gmbh Pterinderivate, ihre Herstellung und ihre Verwendung
DK0689449T3 (da) 1993-03-19 2003-03-03 Vacsyn Sa Præparater til anvendelse i humanterapi, kendetegnet ved kombination af et muramylpeptid med en cytokin
US5449688A (en) 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
US5945452A (en) 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en) 1993-11-29 1996-03-26 Cornell Research Foundation, Inc. Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
TW282398B (es) 1993-12-22 1996-08-01 Bristol Myers Squibb Co
JP3347870B2 (ja) * 1994-04-15 2002-11-20 三菱電機株式会社 超電導マグネット並びに該マグネット用の蓄冷型冷凍機
DE4418096A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
ATE218345T1 (de) 1994-08-05 2002-06-15 Suntory Ltd Arzneimittel gegen spinocerebellare degeneration
US5643586A (en) 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
US5744340A (en) 1995-06-09 1998-04-28 Schering Corporation Expression of human inducible nitric oxide synthase
SE506533C2 (sv) 1995-07-03 1998-01-12 Birger Andersson En process för in vitro analys av substansers toxiska och allergena egenskaper samt användning av neopterin för att skilja mellan allergiska immunreaktioner
US5879690A (en) 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
JP2711828B2 (ja) 1996-06-25 1998-02-10 白鳥製薬株式会社 (6r)−テトラヒドローl−バイオプテリン塩酸塩の製造法
US5856158A (en) 1996-07-05 1999-01-05 University Of Iowa Research Foundation Purified nitric oxide synthase from rat brain
US20020076782A1 (en) 1996-07-05 2002-06-20 John P.N. Rosazza Purified nitric oxide synthase
DE69733308D1 (de) 1996-07-31 2005-06-23 Cmic Co Aktivsauerstoffaufnehmer enthaltende pterinderivate
GB9617990D0 (en) 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
ATE252385T1 (de) 1996-08-30 2003-11-15 Daiichi Suntory Pharma Co Ltd Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
ZA9711548B (en) 1996-12-24 1999-06-23 Res Dev Foundation Ricin inhibitors and methods for use thereof
US6562969B1 (en) 1996-12-24 2003-05-13 Research Development Foundation Ricin inhibitors and methods for use thereof
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
US5846775A (en) 1997-04-22 1998-12-08 Incyte Pharmaceuticals, Inc. GTP cyclohydrolase I regulatory protein
CH693255A5 (de) 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
EP0906913B1 (de) 1997-10-06 2001-05-23 Ernst Werner Pteridinderivate als NO Synthase-Hemmer
AU1189399A (en) 1997-10-15 1999-05-03 Uab Research Foundation Bathocuproine treatment of neurologic disease
EP1004308B1 (en) 1998-02-27 2005-05-11 Daiichi Suntory Pharma Co., Ltd. Preventives or remedies for drug-induced renal disturbance
JP4306825B2 (ja) 1998-02-27 2009-08-05 アスビオファーマ株式会社 インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US6162914A (en) 1998-04-24 2000-12-19 Cerbios-Pharma S.A. Process for the reduction of pterins
US6117872A (en) 1998-06-23 2000-09-12 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of exercise performance by augmenting endogenous nitric oxide production or activity
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
US6346519B1 (en) 1998-09-09 2002-02-12 Advanced Medical Instruments Method and composition for treating arthritis
US6656925B2 (en) 1998-09-09 2003-12-02 Advanced Medical Instruments Composition and method of treating arthritis
US7276506B2 (en) 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
ATE304852T1 (de) 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6200758B1 (en) 1999-02-19 2001-03-13 New York State Office Of Mental Health Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
AU4013900A (en) 1999-03-19 2000-10-09 Enos Pharmaceuticals, Inc. Increasing cerebral bioavailability of drugs
US6288535B1 (en) 1999-07-06 2001-09-11 Jacob Chass Hall effect, shaft angular position sensor with asymmetrical rotor
BR0012793A (pt) 1999-07-28 2002-04-30 Univ Leland Stanford Junior Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina
GB2355191A (en) 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
US20020155445A1 (en) 1999-12-16 2002-10-24 Jarvik Jonathan W. Methods and products for peptide based DNA sequence identification and analysis
AUPQ598300A0 (en) 2000-03-03 2000-03-23 Citrus Sensation Pty Ltd Citrus fruit preservative
US6576105B1 (en) 2000-03-31 2003-06-10 Truman State University Pteridine analysis by capillary electrophoresis using laser-induced fluorescence detection
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6544994B2 (en) 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6660831B2 (en) 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
BR0113411A (pt) 2000-08-31 2004-01-06 Daiichi Suntory Pharma Co Ltd Processo para a produção do composto de biopterina
DE10043845A1 (de) 2000-09-06 2002-03-14 Gruenenthal Gmbh Verfahren zur Messung der Aktivität der NO-Synthase
US6689385B2 (en) 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US6537992B2 (en) 2001-01-05 2003-03-25 John D. Parker Regulation of organic nitrate tolerance
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
US6693094B2 (en) 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
US6500857B1 (en) 2001-08-16 2002-12-31 Nicholas V. Perricone Subcutaneous muscle treatment using electronic stimulation and topical compositions
US20030078231A1 (en) 2001-06-22 2003-04-24 Wilburn Michael D. Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties
US20030004125A1 (en) 2001-06-22 2003-01-02 Hirst David G. Inducible gene
US6787178B2 (en) * 2001-07-09 2004-09-07 Kiyoshi Yamamoto Health drink and method for production thereof
JP4082888B2 (ja) 2001-10-17 2008-04-30 広栄化学工業株式会社 ビアリール化合物の製造法
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
DE10260263A1 (de) 2002-12-20 2004-07-15 Biocrates Life Sciences Gmbh Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
US20070167353A1 (en) 2003-10-24 2007-07-19 John Hilfinger Prodrug composition
BRPI0416566A (pt) 2003-11-17 2007-01-23 Biomarin Pharm Inc tratamento de fenilcetonúrias com bh4
AU2004311544A1 (en) * 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
WO2005049614A2 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
US7067659B2 (en) 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
DK1757293T3 (da) 2004-05-11 2012-10-22 Daiichi Sankyo Co Ltd Bh4-responsiv hyperphenylalaninæmi-medikamenter
EP1768653A4 (en) 2004-06-25 2012-08-01 Univ Texas METHOD AND COMPOSITIONS FOR TREATING ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY AND HYPERPHENYL ALANINEMIA
MX2007005039A (es) * 2004-11-17 2007-06-19 Biomarin Pharm Inc Formulacion de tableta estable.
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
US20060194808A1 (en) 2005-01-14 2006-08-31 Chronorx Llc, An Alaska Limited Liability Company Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate
AU2006321942A1 (en) 2005-12-05 2007-06-14 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of disease
WO2007072911A1 (ja) 2005-12-22 2007-06-28 Asubio Pharma Co., Ltd. 塩酸サプロプテリンの生体内吸収性を向上させた製剤
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
ES2732293T3 (es) 2007-02-22 2019-11-21 Childrens Hospital & Res Center At Oakland Formulaciones de ácidos grasos y métodos para el uso de las mismas
JP5226960B2 (ja) * 2007-02-28 2013-07-03 株式会社スクウェア・エニックス ゲーム装置及び仮想カメラの制御方法、並びにプログラム及び記録媒体

Also Published As

Publication number Publication date
US8003126B2 (en) 2011-08-23
EP2436379A1 (en) 2012-04-04
CA2581814A1 (en) 2006-05-26
US20070270581A1 (en) 2007-11-22
IL182161A0 (en) 2007-07-24
KR20070084270A (ko) 2007-08-24
JP2014012740A (ja) 2014-01-23
BRPI0517088A (pt) 2008-09-30
AU2005306686A1 (en) 2006-05-26
CN101132776A (zh) 2008-02-27
CA2581814C (en) 2015-10-13
WO2006055511A2 (en) 2006-05-26
US20080207626A1 (en) 2008-08-28
AU2005306686B2 (en) 2011-06-02
AR052238A1 (es) 2007-03-07
TW200624120A (en) 2006-07-16
EP1845952A2 (en) 2007-10-24
JP2008520574A (ja) 2008-06-19
MY142120A (en) 2010-09-15
IL182161A (en) 2011-08-31
US7566462B2 (en) 2009-07-28
WO2006055511A3 (en) 2006-10-05
MX2007005039A (es) 2007-06-19

Similar Documents

Publication Publication Date Title
PE20061294A1 (es) Formulacion de tableta estable que contiene polimorfo b de (6r)-l-eritro-tetra hidrobiopterina
DK1755578T3 (da) Tygbar, sugbar og slugbar tablet indeholdende en calcium-holdig forbindelse som aktivt stof
AR069312A1 (es) Composicion farmaceutica que comprende beta oxihidroxido de hierro en alta carga en forma adecuada para administarcion oral y que contiene al menos un hidrato de carbono y/o acido humico y su uso en el tratamiento de pacientes con hiperfosfatemia y con insuficiencia renal cronica , y procedimento pa
HRP20161231T1 (hr) Farmaceutske formulacije koje sadrže derivate 1-(beta-d-glukopiranozil)-2-tienilmetilbenzena kao sglt inhibitore
JP2010047612A5 (es)
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
MX2009012619A (es) Formulacion farmaceutica estable para un inhibidor de dpp-iv.
GB0722077D0 (en) Compounds
CO6220902A2 (es) Formulacion en polvo del valganciclovir
BR112014014795A2 (pt) sistema de pélete de multiunidade de liberação imediata
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
UY27759A1 (es) Combinaciones de medicamentos que contienen compuestos heterocíclicos y un nuevo agente anticolinérgico.
PE20040416A1 (es) Formulacion de alta dosis de ibandronato
BR112012026714A2 (pt) pastilhas de eritritol e isomalte
JP6062705B2 (ja) 医薬組成物
PE20091418A1 (es) Formulaciones de flibanserina
MX2009006114A (es) Composiciones que comprenden carisoprodol y metodos de uso de las mismas.
AR096725A1 (es) Formulación de comprimidos masticables que comprende tadalafil o una de sus sales aceptables desde el punto de vista farmacéutico
AR094146A1 (es) Unidad solida con alto contenido en fexofenadina y su procedimiento de preparacion
PE20142460A1 (es) Composiciones farmaceuticas orales estables de liberacion inmediata que contienen prasugrel
HRP20200472T1 (hr) Liječenje alopecije areate
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
PE20090316A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antimicrobiano y un agente antioxidante para el tratamiento de infecciones urinarias

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed